Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Return on Capital Employed (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Return on Capital Employed for 8 consecutive years, with 0.38% as the latest value for Q4 2024.

  • On a quarterly basis, Return on Capital Employed fell 5.0% to 0.38% in Q4 2024 year-over-year; TTM through Dec 2024 was 0.38%, a 5.0% decrease, with the full-year FY2024 number at 0.34%, down 10.0% from a year prior.
  • Return on Capital Employed was 0.38% for Q4 2024 at Akebia Therapeutics, down from 0.33% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.2% in Q1 2023 to a low of 0.94% in Q1 2022.
  • A 5-year average of 0.57% and a median of 0.51% in 2023 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: plummeted -35bps in 2021, then soared 73bps in 2023.
  • Akebia Therapeutics' Return on Capital Employed stood at 0.8% in 2020, then dropped by -9bps to 0.87% in 2021, then skyrocketed by 66bps to 0.3% in 2022, then dropped by -12bps to 0.33% in 2023, then fell by -14bps to 0.38% in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Return on Capital Employed are 0.38% (Q4 2024), 0.33% (Q4 2023), and 0.32% (Q3 2023).